Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on oncology drug development that came public through a merger with Panacea Acquisition Corp. II, a healthcare-focused SPAC sponsored by Panacea Acquisition Management II LLC that completed its IPO in 2020. The company filed an S-1 registration statement with the SEC on March 11, 2021, accession number 0001193125-21-077946, in connection with the de-SPAC business combination. Nuvation Bio, founded by oncology entrepreneur David Hung, targets difficult-to-treat cancers with a pipeline of novel small-molecule therapeutics. Following the transaction's close, the combined company began trading on the New York Stock Exchange under the ticker NUVB. Sign up for full data, filings history, and deal analytics on SpacDesk.